Fresenius Medical Care AG & Co. KGaA

Investor Presentation • Feb 22, 2012

Corporate Profile

Fresenius Medical Care

Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2.1 million individuals worldwide. Through its network of 2,898 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 233,156 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.

Growth Strategy

With GOAL 13…

…new targets of the growth strategy were adopted in September 2010. Thereby we follow up the previous strategy, continuing to pursue the strategic four paths consistently in a financially responsible way to consolidate our position as world market leader in dialysis:

• Organic growth in dialysis services by innovative treatment techniques and the opening of new clinics
• Acquisitions of existing clinics to ensure optimized international presence
• Horizontal expansion in the sector of Renal Drugs as well as
• A boosted activity in home therapies

Key Figures - Summary Full Year 2011

Net revenue	\$ 12,795 million	+ 6%
Operating income (EBIT)	\$ 2,075 million	+ 8%
Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA	\$ 1,071 million	+ 9%
Earnings per share	\$ 3.54	+ 9%
Total assets1	\$ 19,533 million
Operating cash flow2	\$ 1,446 million
Employees1	79,159	+ 8%
Patients1	233,156	+ 9%
Clinics1	2,898	+ 6%
Treatments2	34.39 million	+ 9%
1 as of December 31, 2011

2

in the full year of 2011

Revenue full year 2011 per region (US\$ 12,795 m)

Goals for 2012

Net revenue	~ \$14.0 billion
Net income	~ \$1.14 billion
Leverage ratio (Debt/EBITDA)	< 3.0
Capital expenditures	~ \$700 million
Acquisitions	~ \$1.8 billion

Management Board Supervisory Board

• Dr. Ben J. Lipps (Chairman) Dr. Gerd Krick (Chairman)

• Kent Wanzek

• Rice Powell (Vice Chairman) Dr. Dieter Schenk (Vice Chairman)

• Michael Brosnan Dr. Walter L. Weisman
• Roberto Fusté Rolf A. Classon
• Dr. Emanuele Gatti William P. Johnston
• Dr. Rainer Runte Prof. Dr. Bernd Fahrholz

Share Profile – Key Data

Ticker Symbols	Ordinary shares	Preference shares
Frankfurt Stock Exchange	FME	FME3
New York Stock Exchange (NYSE)	FMS	FMS/P
Reuters: XETRA / Frankfurt Stock Exchange	FMEG.DE / FMEG.F	FMEG_p.DE / FMEG_p.F
Bloomberg	FME GY	FME3 GY
Security Identification Numbers
WKN	578 580	578 583
ISIN	DE 0005785802	DE 0005785836
CUSIP No. (NYSE)	358029106	358029205

Financing Instruments and Maturity Profile

Amount	Coupon %	Maturity
in million
\$ 1,200		March 31, 2013
		March 31, 2013
		March 31, 2013
€ 250	5.50%	July 15, 2016
€ 100	3-month-Euribor +3.50%	Oct. 15, 2016
\$ 500	6.875%	July 15, 2017
\$ 400	6.50%	September 15, 2018
€ 400	6.50%	September 15, 2018
\$ 800	5.625%	July 31, 2019
€ 250	5.25%	July 31, 2019
\$ 650	5.75%	February 15, 2021
€ 300	5.25%	February 15, 2021
\$ 700	5.875%	January 31, 2022
€ 155		October 27, 2012
€ 45		October 27, 2014
\$ 800		July 31, 2014
	\$ 1,8501 \$ 1,7501

at the beginning before amortisation and extension

Share Price Development last 12 months Financial Calendar

Capital Structure Contacts

Event	Date
Report on Full Year 2011
Annual Financial Report:	March 30, 2012
Report on First Quarter 2012:	May 3, 2012
Annual General Meeting:	May 10, 2012
Payment of Dividend1 :	May 11, 2012
Report on Second Quarter 2012:	August 1, 2012
Report on Third Quarter 2012:	October 31, 2012
1

Subject to the approval of the AGM

Fresenius Medical Care AG & Co. KGaA Investor Relations & Corporate Communications
Else-Kröner-Straße 1	61352 Bad Homburg
Oliver Maier	P:+49(0)6172-609-2525
Senior Vice President, Head of IR & CC	F: +49(0)6172-609-2301
Gerrit Jost Vice President	P:+49(0)6172-609-5216
North America Terry L. Morris Vice President	P:+1-800-948-2538 F: +1-615-345-5605